Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NQO2 | P16083 | 3/20 | 0.39 |
| ▸ | NQO1 | P15559 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA7 | P43166 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.33 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.33 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20116552 | 0.82 | KDM4E (0.40) | KMT2AALDH1A1MAPTKDM4ENPC1 | |
| SCHEMBL1850824 | 0.82 | KDM4E (0.40) | KMT2AALDH1A1MAPTKDM4EAPP | |
| SCHEMBL2908830 | 0.82 | TRPM8 (0.43) | NQO2NQO1ALDH1A1MAPTKDM4E | |
| SCHEMBL2908835 | 0.81 | PDE4B (0.35) | KMT2AKDM4ECYP1A2CYP2C19NPC1 | |
| SCHEMBL16741129 | 0.81 | KMT2A (0.33) | KMT2AAPP | |
| SCHEMBL30454032 | 0.80 | NQO2 (0.39) | NQO2NQO1CA12CA1CA2 | |
| SCHEMBL130142 | 0.80 | NQO2 (0.39) | NQO2NQO1CA12CA1CA2 | |
| SCHEMBL2908833 | 0.79 | FPR2 (0.41) | KMT2AALDH1A1MAPTKDM4ECYP1A2 | |
| SCHEMBL28511868 | 0.79 | NQO2 (0.40) | KMT2ANQO2NQO1CA12CA1 | |
| SCHEMBL1070329 | 0.77 | KDM4E (0.50) | NQO2NQO1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250270210-A1 | BCL-2 Inhibitor | BEIGENE, LTD. (KY) | 2025-08-28 | — | — | US | disclosed |
| US-20250197375-A1 | PYRIMIDINES AND METHODS OF THEIR USE | Kineta, Inc. | 2025-06-19 | — | — | US | disclosed |
| WO-2025129168-A1 | TRIAZOLONE INHIBITORS OF NICOTINAMIDE N-METHYLTRANSFERASE AND THEIR THERAPEUTIC USES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2025-06-19 | — | — | WO | disclosed |
| US-20250179087-A1 | COMPOUNDS AND THEIR USES AS LPAR5 ANTAGONISTS | Immunophage Biotech (Shanghai) Co., Ltd. (CN) | 2025-06-05 | — | — | US | disclosed |
| US-12286430-B2 | Bcl-2 inhibitor | BEIGENE, LTD. (KY) | 2025-04-29 | — | — | US | disclosed |
| US-20250114374-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. | 2025-04-10 | — | — | US | disclosed |
| WO-2025076285-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME | DELPHIA THERAPEUTICS, INC. (US) | 2025-04-10 | — | — | WO | disclosed |
| US-20250099481-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. | 2025-03-27 | — | — | US | disclosed |
| CN-119403800-A | Compounds and their use as LPAR5 antagonists | 艾美斐生物医药科技(上海)有限公司 | 2025-02-07 | — | — | CN | disclosed |
| EP-4486742-A1 | COMPOUNDS AND THEIR USES AS LPAR5 ANTAGONISTS | IMMUNOPHAGE BIOTECH (SHANGHAI) CO., LTD. (CN) | 2025-01-08 | — | — | EP | disclosed |
| WO-2009001127-A1 | CYANOCYCLOPROPYLCARBOXAMIDES AS CATHEPSIN INHIBITORS | ASTRAZENECA AB (SE) | 2008-12-31 | — | — | WO | disclosed |
| US-20080045561-A1 | Novel Bis-Azaindole Derivatives, Preparation And Pharmaceutical Use Thereof As Kinase Inhibitors | AVENTIS PHARMA S.A. (FR) | 2008-02-21 | — | — | US | disclosed |
| US-20080045561-A1 | Novel Bis-Azaindole Derivatives, Preparation And Pharmaceutical Use Thereof As Kinase Inhibitors | AVENTIS PHARMA S.A. (FR) | 2008-02-21 | — | — | US | disclosed |
| US-20080045561-A1 | Novel Bis-Azaindole Derivatives, Preparation And Pharmaceutical Use Thereof As Kinase Inhibitors | AVENTIS PHARMA S.A. (FR) | 2008-02-21 | — | — | US | disclosed |
| CN-101052642-A | Novel bis-azaindole derivatives, their preparation and their pharmaceutical use as kinase inhibitors | AVENTIS PHARMA SA (FR) | 2007-10-10 | — | — | CN | disclosed |
| EP-1799691-A1 | NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS | Aventis Pharma S.A. (FR) | 2007-06-27 | — | — | EP | disclosed |
| US-20070049611-A1 | Phosphodiesterase 4 inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-01 | — | — | US | disclosed |
| CN-1922144-A | Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs | MEMORY PHARM CORP (US) | 2007-02-28 | — | — | CN | disclosed |
| WO-2006037875-A1 | NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2006-04-13 | — | — | WO | disclosed |
| US-20050222207-A1 | Phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs | MEMORY PHARMACEUTICAL CORPORATION | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250114374-A1 | BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L10 | KMT2A 1106/4885NQO2 67/4885NQO1 644/4885 |
| US-20080045561-A1 | Novel Bis-Azaindole Derivatives, Preparation And Pharmaceutical Use Thereof As Kinase Inhibitors | BRSK2, KSR2, CDK2 | KMT2A 851/4885NQO2 696/4885NQO1 2488/4885 |
| US-20250099481-A1 | BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L10 | KMT2A 1000/4885NQO2 75/4885NQO1 555/4885 |
| US-20070049611-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE3B, PDE4B | KMT2A 2034/4885NQO2 242/4885NQO1 938/4885 |
| US-20250270210-A1 | BCL-2 Inhibitor | BCL2, BCL2A1, BCL2L1 | KMT2A 2445/4885NQO2 888/4885NQO1 1678/4885 |
| US-20050222207-A1 | Phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs | PDE4A, PDE4B, PDE3B | KMT2A 1702/4885NQO2 126/4885NQO1 423/4885 |
| US-20250197375-A1 | PYRIMIDINES AND METHODS OF THEIR USE | TDP1, TYMP, TARDBP | KMT2A 3312/4885NQO2 1451/4885NQO1 568/4885 |
| US-12286430-B2 | Bcl-2 inhibitor | BCL2, BCL2A1, BCL2L1 | KMT2A 2445/4885NQO2 888/4885NQO1 1678/4885 |
| US-20250179087-A1 | COMPOUNDS AND THEIR USES AS LPAR5 ANTAGONISTS | LPAR5, LPAR3, LPAR2 | KMT2A 2485/4885NQO2 1605/4885NQO1 2615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.